Drug-eluting and plain balloon angioplasty produce similar results at three years when treating femoropopliteal in-stent restenosis, according to new data from the DEBATE-ISR trial.
The first patient suffering from post-thrombotic syndrome associated with venous outflow obstruction has been treated with the VICI VERTO VENOUS STENT system.
AV Medical Technologies has announced the culmination of a 30-patient study that evaluated the proprietary design of the Chameleon angioplasty balloon catheter.
QT Vascular has submitted an investigational device exemption (IDE) for permission to begin the pivotal study of the Chocolate Touch drug-coated balloon in the USA.
Medtronic has announced with several new presentations that showed durable and consistent clinical outcomes in the most challenging patients with peripheral artery disease. The new data, presented at the 2016 Charing Cross Symposium (26–29 April, London, UK), included the one-year results from the chronic total occlusion imaging cohort from the IN.PACT Global Study and the two-year gender and diabetic subgroup analyses from the pivotal IN.PACT SFA Trial.
Now that non-thrombotic iliac vein lesions (NIVLs) are more frequently recognised on modern imaging modalities, they are beginning to trigger a paradigm shift in standard vein work whereby there is now increasing emphasis on making sure that these patients do not have significant deep venous obstruction which must be taken into account when planning treatment.
The CX Peripheral Arterial Challenges session at the 2016 Charing Cross Symposium (CX 2016; 25–29 April, London, UK) saw a host of new developments being presented and a lift for drug-coated balloons (DCBs), swirling flow stents and drug-eluting stents.
Two 2016 Charing Cross Symposium (CX 2016; 26–29 April, London, UK) presentations in the Venous Challenges Main Programme session have demonstrated the value of dedicated venous stents, with interim results from two studies in patients with symptomatic iliofemoral venous outflow obstruction showing symptom improvement 12-months post-stent placement.
A presentation at the Abdominal Aortic Aneurysm Challenges session during the 2016 Charing Cross Symposium (26–29 April, London, UK) has compared the ENGAGE global registry with results from the landmark EVAR 1 trial. The ENGAGE post-market registry has collected data on the Endurant abdominal aortic aneurysm (AAA) stent graft system (Medtronic).
Endologix has announced the presentation of positive clinical data for the Nellix EndoVascular Aneurysm Sealing (EVAS) system at the 38th Annual Charing Cross Symposium (26–29 April, London, UK). This includes updated data from the Nellix EVAS-FORWARD–Global Registry and a data presentation from Jean-Paul de Vries (Nieuwegein, Netherlands) entitled “Endovascular sealing of common iliac artery aneurysms—multicentre experience”. The Nellix EVAS system is approved for investigational use only in the USA.
Gore has joined with leaders across the vascular and endovascular community in honouring four European physicians as Pioneers in Performance at the 2016 Charing Cross Symposium (26–29 April, London, UK). The biennial award acknowledges exceptional work in the field of vascular and endovascular therapy, including aortic and lower-limb bypass and dialysis access surgery.
Shockwave Medical has announced positive clinical results from the pooled DISRUPT PAD Study, a single-arm, two-phase multicentre study evaluating the safety and performance of Lithoplasty system to treat peripheral artery disease, at the Charing Cross 2016 Symposium (26–29 April, London, UK).
The teams of researchers and principal investigators who collected and analysed the data for the Individual Patient Data meta-analysis and EVAR 1 trial presented the data in the session titled “EVAR follow-up and avoidance of secondary sac rupture and death” at the 2016 Charing Cross Symposium (CX 2016; 26–29 April, London, UK).
Since its introduction in the late 80s, endovascular therapy has become increasingly widespread and important. A mini-symposium held at the 2016 Charing Cross Symposium (26–29 April, London, UK), brought to the fore the radiation damage that has occurred to pioneering operators in the field. It also focused on currently available methods to reduce radiation exposure during endovascular procedures.
At one of the 2016 Charing Cross (CX 2016; 26–29 April, London, UK) Great Debates, a small majority of the audience (53%) voted against the motion “In chronic type B dissection, there is no place for false lumen embolisation—true lumen TEVAR is preferred”. The voting signalled victory for Fabrizio Fanelli, Rome, Italy, and Tilo Kölbel, Hamburg, Germany, who cleverly unpicked the motion to show that if false lumen embolisation was used even in select cases, it would go against the motion. Peter Mossop, Melbourne, Australia and Stephan Haulon, Lille, France, argued for the motion, and made the case that false lumen embolisation had no place in chronic type B dissection.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos